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EpigeneticA prominent role of epigeneticmechanisms inmanifestation of epilepsy has been proposed. Thus altered histone
H3 and H4 acetylation has been demonstrated in experimental models of temporal lobe epilepsy (TLE).We now
investigated changes in the expression of the class I and class IV histone deacetylases (HDAC) in two complemen-
tary mouse TLE models. Unilateral intrahippocampal injection of kainic acid (KA) induced a status epilepticus
lasting 6 to 24 h, development of spontaneous limbic seizures (2 to 3 days after KA injection) and chronic epilep-
sy, as revealed by telemetric recordings of the EEGs. Mice were killed at different intervals after KA injection and
expression of HDACmRNAs was investigated by in situ hybridization. We observed marked decreases in the ex-
pression of HDACs 1, 2 and 11 (by up to 75%) in the granule cell and pyramidal cell layers of the hippocampus
during the acute status epilepticus (2 to 6 h after KA injection). This was followed by increased expression of
all class I HDAC mRNAs in all principal cell layers of the hippocampus after 12 to 48 h. In the chronic phase, 14
and 28 days after KA, only modest increases in the expression of HDAC1 mRNA were observed in granule and
pyramidal cells. Immunohistochemistry using an antibody detecting HDAC2 revealed results consistent with
the mRNA data and indicates also expression in glial cells on the injection side. Similar changes as seen in the
KA model were observed after a pilocarpine-induced status epilepticus except that decreases in HDACs 2, 3
and 8 were also seen at the chronic 28 day interval.
The prominent decreases in HDAC expression during status epilepticus are consistent with the previously
demonstrated increased expression of numerous proteins and with the augmented acetylation of histone H4.
It is suggested that respective putative gene products could facilitate proconvulsive as well as anticonvulsive
mechanisms. The increased expression of all class I HDACs during the “silent phase”, on the other hand, may
be related to decreased histone acetylation, which could cause a decrease in expression of certain proteins, a
mechanism that could also promote epileptogenesis. Thus, addressing HDAC expression may have a therapeutic
potential in interfering with a status epilepticus and with the manifestation of TLE.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Temporal lobe epilepsy (TLE) is the most common and difﬁcult to
treat form of focal epilepsies. It comprises about 30% of all epilepsies
(Fisher et al., 1998). The most common pathology underlying TLE is
Ammon's horn sclerosis and sprouting of mossy ﬁbers. Neurodegenera-
tion affects primarily the hilus of the dentate gyrus and hippocampal
sectors CA3 and CA1 while other brain areas are less affected (Babbthyl-isoxazole-propionic acid;
AC, histone deacetylase; TLE,
c factor.
logy, Peter-Mayr-Str. 1a, 6020
).
. This is an open access article underet al., 1984). In some instances dispersion of the granule cell layer is
observed (Houser, 1990; Haas et al., 2002). In general, TLE develops
after an initial insult, which e.g. can be early febrile seizures, brain
trauma or a status epilepticus. However, it may take years from this
initial insult until the ﬁrst clinical symptoms of TLE occur. This time
window is often termed as “silent phase” and during this period
plastic changes develop in brain circuitries ultimately leading to epilepsy.
In theory, this phase would offer an ideal opportunity to suppress the
process of epileptogenesis by drug therapy and thereby preventmanifes-
tation of TLE. However, no such “disease modifying” drug has been
discovered yet.
A variety of animal models have been developed for investigating
changes in molecular and cellular mechanisms that accompany or
even may be causatively related to manifestation of epilepsy. These
animal models are mostly based on the induction of a status epilepticus
by applying repeated electrical stimulation or injections of convulsive
toxins, such as kainic acid (KA) or pilocarpine, or by triggering febrilethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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lent phase is variable, however, spontaneous seizures develop mostly
after 1 to 3 weeks (Rakhade and Jensen, 2009; Williams et al., 2009;
Drexel et al., 2012b). Altered gene expression induced by the initial
insult (status epilepticus) may be related to molecular and cellular
mechanisms leading to the development of epilepsy. These include
augmented expression of immediate early genes, growth factors,
inﬂammation associated proteins and neuropeptides (Gass et al.,
1992; Esclapez and Houser, 1999; Vezzani et al., 2011; Sperk et al.,
2012; Clynen et al., 2014).
These complex epilepsy-induced changes in gene expression of
multiple proteins are presumably guided by epigenetic mechanisms,
including chromatin modiﬁcations (McClelland et al., 2011) such as
DNA methylation or histone modiﬁcations (Hwang et al., 2013; Kobow
and Blumcke, 2014). DNA methylation is mostly targeting CpG dinucleo-
tides of the chromatin and is catalyzed by a family of DNAmethyltransfer-
ases (Holliday and Pugh, 1975). Histone modiﬁcations include
acetylation,methylation, phosphorylation andothermodiﬁcations of spe-
ciﬁc amino acids in the N-terminal tail of histones (Khorasanizadeh and
Ostankovitch, 2014). Some modiﬁcations may activate gene expression,
while others inhibit. Among these modiﬁcations histone methylation
and acetylation have been extensively studied in recent years. Histone
acetylation is catalyzed by histone acetyltransferases and reversed by his-
tone deacetylases (HDACs). Acetylated histones, H3 and H4, generally re-
ﬂect a more permissive (open) state of chromatin and thereby increased
gene expression, whereas deacetylation mostly suppresses transcription
(Kimura et al., 2005). In humans and rodents, multiple HDAC enzymes
have been identiﬁed. Based on their homology to yeast histone
deacetylases they are divided into four major classes (Chuang et al.,
2009). Class I HDACs include HDAC1, 2, 3 and 8. Class II HDACs comprise
HDAC4, 5, 6, 7, 9 and 10. Class III HDACs are referred to as sirtuins (SIRT1–
SIRT7) based on their homology to the yeast HDAC Sir2. They are more
general protein deacetylases. Due to its distinct structure, HDAC11 has
been attributed to an ownclass, class IV (Voelter-Mahlknecht et al., 2005).
To investigate a possible role of the expression of HDACs during the
development of epilepsy we now investigated changes in the mRNA
levels of class I and IV HDACs. We used a mouse model based on
unilateral local injection of KA (Riban et al., 2002). The model induces
early spontaneous seizure activity (epilepsy) and granule cell disper-
sion at the site of KA injection. We compared this model with the
more broadly used model based on i.p. injection of pilocarpine
(Cavalheiro et al., 1996). The concomitant use of both models allowed
us to exclude individual aspects of the models (such as the use of
different receptor agonists for inducing the status epilepticus) when
studying changes in HDAC expression during seizure induction and
epileptogenesis in the “silent phase”. In an accompanying study we
investigated changes in class II HDAC expression in the same animal
models (Jagirdar et al., unpublished results). This study revealed signif-
icantly different changes for class II HDACs (particularly in relation to
granule cell dispersion) as reported here for class I and IV HDACs (see
discussion).
2. Materials and methods
2.1. Animals
All animal experiments were conducted according to national
guidelines and European Community laws and were approved by the
Committee for Animal Protection of the Austrian Ministry of Science. In
total, we used 91 adult, 10–16 weeks old, male C57Bl6/N mice
(25–30 g; Charles River Laboratories, Sulzberg, Germany) for local
injection of KA, 18 mice for injection of pilocarpine and 33 control
mice. The animals were housed in groups of 3–5 in Sealsafe™ IVC
cages (Techniplast GmbH, Hohenpeissenberg, Germany) under
standard laboratory conditions (12/12 h light/dark cycle, light turns
on at 06:30 AM). They had access to food and water ad libitum.2.2. Surgical procedures
2.2.1. Anesthesia and presurgical procedures
The mice were given analgesic treatment (5 mg/kg carprofen s.c.;
Rimadyl, Pﬁzer, USA) 60 min prior to the surgery and were then
anesthetized by injection of 150 mg/kg ketamine (Ketasol, stock
solution: 50 mg/ml, Ogris Pharma Vertriebs-GmbH, Wels, Austria).
Anesthesia was maintained with 1–4% of sevoﬂurane (Sevorane®,
Abbott, Vienna, Austria) applied through a veterinary anesthetic mask
(VIP 3000, Matrx by Midmark, USA) throughout the entire procedure.
The deeply anesthetized mice were ﬁxed in a stereotaxic frame (David
Kopf Instruments, California, USA) using ear-bars.
2.2.2. Stereotaxic injections of kainic acid (KA)
KA injection was done unilaterally into the area of the stratum
lacunosum/radiatumCA1 of the dorsal hippocampus of themice. The fol-
lowing stereotaxic coordinates were used: anterioposterior,−1.9 mm;
mediolateral, ±1.6 mm; and dorsoventral,−1.9 mm from bregma. The
coordinates were determined using the mouse brain atlas by Franklin
and Paxinos (2008) and were veriﬁed in brain sections from methylene
blue injected mice. At the anterioposterior/mediolateral coordinates
small holes (0.7 mm in diameter) were drilled into the scull at both
sides using a dental drill for applying KA and the recording electrode
(both left side) and the reference electrode (contralateral side),
respectively.
KA (Ascent Scientiﬁc Ltd., North Somerset, United Kingdom; 350
pmoles in 70 nl in a solution of 5 mM in 0.9% NaCl, adjusted to pH 7.0)
was infused unilaterally on the right side at a rate of 0.14 μl/min using
a 5 μl Hamilton syringe (Neuros™ Hamilton Syringe, 7000.5, Hamilton
Bonaduz AG, Switzerland) connected to a syringe pump (QSI™,
Stoelting, IL, USA). After injection the needle was withdrawn slowly
(5 min). Controls were injected with saline (70 nl).
2.2.3. Implantation of electrodes and of telemetric transmitters
Immediately after infusion of KA, mice were implanted with
biopotential transmitters (TA10EA-F20; Data Sciences International,
Arden Hills, USA). For this, an incision was made (max. 2 cm,
rostrocaudally) at the center of a shaved area at the abdomen and a
subcutaneous cavity was formed using Metzenbaum scissors. Then a
subcutaneous passage to the skull was formed using a bulb-headed
probe (2 mm) and the electrode leads of the transmitter were pulled
from the subcutaneous cavity to the opened scalp using a thin forceps.
The transmitter was placed into this cavity and the incisionwas sutured
using Supramid (USP 4/0, multiﬁlament, non absorbable) surgical
thread (Supramid TC158000, Serag Wiessner, Naila, Germany).
The recording electrode was placed epidurally through the same
hole set for infusion of KA. The reference electrode was placed in the
same way on the contralateral side. The electrodes were ﬁxed to the
scull by setting three stainless steel screws (M1*2, Hummer und Rieß
GmbH, Nürnberg, Germany) in an epidural position and by embedding
the electrodes and the screws in dental cement (Paladur—Heraeus
Kulzer, Henry Schein, Austria). The scalp skin was then closed using
Supramid. After surgery the body temperature of the mice was
stabilized using a red light lamp. The mice received a second dose of
carprofen (5 mg/kg; s.c.) after 24 h.
2.3. EEG-telemetry and video monitoring
Transmitter implanted mice were single housed in single ventilated
cages with agarose gels (1 g agarose in 100ml of 2% sucrose) as a water
source in addition to food pellets, oat ﬂakes and water. The EEGs were
recorded using an EEG-telemetry system (Dataquest A.R.T., Data
Acquisition 4.0 for telemetry systems, Data Sciences International,
Arden Hills, USA). EEG signals emitted by the transmitters were cap-
tured with receiver plates placed under each cage and transmitted to
a computer (Windows XP operating system, Microsoft) through a data
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stored in external hard drives. Behavioral responses were captured by
video monitoring using infra-red sensitive Axis 221 network cameras
(Axis Communications AB, Lund, Sweden). Mice were kept under 12 h
light/dark cycle but with infrared lighting (Conrad Electronics GmbH,
Wels, Austria) during the dark phase.
2.4. EEG analysis
EEGs were recorded at a sampling rate of 1000 Hz with no a priori
ﬁlter cut-off and started 30min after surgery. EEG traceswere inspected
visually. Increased EEG activity was deﬁned by continuous synchronous
high-frequency and high-amplitude oscillations (N2 × baseline
amplitude), by obvious progression of spike frequency and a minimum
duration of 10 s. Additionally, prolonged periods of increased
EEG-activity were checked for post-ictal depression of the EEG signal
(below baseline EEG activity) considered as a typical sign of seizures
(Bouilleret et al., 1999; Williams et al., 2009).
Seizure-like activitywas categorized into “hippocampal paroxysmal
discharges” (HPD) and “spontaneous strong seizures”. As HPD we de-
ﬁned high frequency oscillations with an amplitude of at least double
the baseline and a duration of 10–30 s. Spontaneous strong seizures
were characterized by high frequency and high amplitude oscillations
(more than 2–3 times baseline). In contrast to HPD, spontaneous strong
seizures gradually progressed, lasted for more than 30 s, and were
directly followed by post-ictal depression of the EEG-amplitude before
returning to baseline.
2.4.1. Motor seizure rating
Recording of EEG signals and video recording were synchronized
and were performed continuously for 28 days after KA injection. Sei-
zures deﬁned by EEG were investigated for a behavioral correlate by
inspecting the synchronized video recordings and, according to this,
were classiﬁed as clinical or subclinical seizures. Seizure rating was
done in accordance to that of KA-injected rats (Sperk et al., 1983):
Stage 1, staring, arrest, chewing; stage 2, unilateral or bilateral tonic
movements/seizure; stage 3, rearing without falling; stage 4, rearing
with falling, limbic seizures; stage 5, death.
2.5. Pilocarpine-induced seizures
For identifying changes in HDAC expression speciﬁcally related to
seizure induction and epileptogenesis and not to particular effects of
the KA model we investigated changes in HDAC expression also the pi-
locarpine model of epileptogenesis (Cavalheiro et al., 1996). Male mice
(20 to 25 g) were injected with N-methyl scopolamine (170 mg/kg in
saline; s.c.) and after 20 min with pilocarpine (Pitsch et al., 2007). All
mice rapidly developed seizures leading to a status epilepticus and
were treated with 4 mg/kg i.p. diazepam (Gewacalm, Nycomed, Linz,
Austria) 40 min after the ﬁrst stage 3 seizure. Control mice were
injected with N-methyl scopolamine followed by saline injections.
Seizures were rated according to the same rating scale given above.Table 1
Sequences of DNA probes.
Probe DNA sequence
mHDAC1 GAA CTC AAA CAA GCC ATC AAA CAC CGG ACA GTC CT
mHDAC1 GTT CTG GTT GGT CAT GTT GGA AGG GCT GAT GTG AA
mHDAC2 GAT CAG CAA CAT TCC TAC GAC CTC CTT CAC CTT CAT
mHDAC2 AGC ACC AAT ATC CCT CAA GTC TCC TGT TCC AGG
mHDAC3 ACC CTC TCC TCC TTG CCA CTG TAC TTC ATC TGC AGT
mHDAC8 GTC AAA TAT CCC TTC TGT GGC TGG GCA GTC AT
mHDAC8 GTG CAG GGA CAC AGT CAT AAC CTT CGA TGT
mHDAC11 CAG GTC TGT CTG GAC CTT GAC TTA TTG AGG GG
mHDAC11 CGA GAT CAA TGA TGG TGG CTC TGG AGA TGC CTT CC2.6. Tissue preparation
For in situ hybridization, KA injected mice were killed in a CO2-
chamber at different time intervals including short-time intervals, 2 h,
4 h, 6 h, 12 h, 24 h and 48 h and long-time intervals 7 days, 14 days and
28 days. In the pilocarpine experiment mice were killed 4 h, 24 h, and
28 days after pilocarpine injection. Mice were then immediately
decapitated. The brains were removed and snap frozen in isopentane
(−70 °C for 3 min). They were then kept at−70 °C in open tubes for
24 h to allow the isopentane to evaporate and then stored in sealed
vials. Coronal 20 μm sections were cut with a cryotome (HM 560 M,
Microm GmbH, Walldorf, Germany) and thaw-mounted onto gelatine-
coated slides. The sections were stored at−20 °C until further use.
For immunocytochemistry, injected mice were killed at different
intervals (4 h, 12 h, 24 h, 14 days) after KA injection by transcardial
perfusion with with 4% paraformaldehyde in 50-mmol/l phosphate
buffer, pH 7.4 as described previously (Drexel et al., 2012a). Brains
were snap-frozen in−70 °C isopentane (Merck, Darmstadt, Germany)
for 3 min and stored at−70 °C. Coronary 30-μm-sections were cut on
a cryostat microtome (Carl Zeiss AG, Vienna, Austria), collected in
50-mmol/l Tris-buffered saline containing 0.1% NaN3 (all from Merck),
and stored at 4 °C.
2.7. In situ hybridization
2.7.1. Oligonucleotides
Oligonucleotides complementary to the mRNA sequences of the in-
dividual HDACs were designed and obtained HPLC puriﬁed from
Microsynth (Balgach, Switzerland). They are listed in Table 1.
In situ hybridizationwas performed as described previously in detail
(Furtinger et al., 2001). Oligonucleotides (2.5 pmol)were 3′ end-labeled
with [33P]α-dATP (75 μCi; 3000 Ci/mmol, SCF-203, Hartmann Analytic,
Braunschweig, Germany) and terminal transferase (Roche Diagnostics,
Basel, Switzerland), as described previously in detail (Drexel et al.,
2012a). Hybridization was performed in 50% formamide, 4× SSC (1×
SSC is 150 mMNaCl, 15 mM sodium citrate, pH 7.2), 500 μg/ml salmon
spermDNA, 250 μg/ml yeast tRNA, 1×Denhardt's solution (0.02% Ficoll,
0.02% polyvinylpyrrolidone, and 0.02% bovine serum albumin), 10%
dextran sulfate, and 20 mM dithiothreitol (all from Sigma) at 42 °C for
18 h. The slides were washed stringently (50% formamide in 1× SSC,
42 °C) and then rinsed in water brieﬂy, followed by 70% ethanol, and
dried. They were then exposed to BioMax MR ﬁlms (Amersham
Pharmacia Biotech, Buckinghamshire, UK) together with [14C]-micro-
scales for 14 to 28 days. The ﬁlms were developed with Kodak D19 de-
veloper. Sections were counterstained with cresyl violet, dehydrated,
cleared in butyl acetate, and covered using Eukitt (Merck, Darmstadt,
Germany).
2.8. Immunohistochemistry
Paraformaldehyde-ﬁxed sections were processed for immunohisto-
chemistry as described in detail previously (Drexel et al., 2012a). The
free-ﬂoating mouse brain sections were pre-incubated with mouse IgGenBank no. Bases
C ACC NM_008228.2 306–344
G CTT NM_008228.2 1041–1079
CCT CAG NM_008229.2 1479–1520
NM_008229.2 827–859
T NM_010411.2 1793–1829
NM_027382.3 383–414
NM_027382.3 658–687
NM_144919.2 1592–1623
A NM_144919.2 537–572
Fig. 1. EEG activity induced by intra-hippocampal injection of kainic acid (KA). A, The initial status epilepticus reaches amaximumafter 6 to 10 h. B. Saline injectedmouse. C–F, EEGs taken
12 days after the initial status epilepticus. C. Trace showing hippocampal paroxysmal discharges (HPD; arrows); D, trace showing HPD and a strong spontaneous seizure. E and F, larger
magniﬁcation of a HPD and a strong seizure, respectively. The arrows mark the beginnings and ends. Note the higher amplitude and the post-seizure depression of the strong seizure (F).
Fig. 2. Development of motor seizures after injection of kainic acid (KA). Strong EEG sei-
zures (Fig. 1F) were recorded telemetrically 3 days after injection of KA and thereafter at
a rate of 0 to 2 per 24 h. Using the behavioral video recordings, we evaluated the motor
seizures occurring concomitantly with each strong EEG seizure. The following seizure rat-
ing scale was used: stage 0, no motor signs; stage 1, staring, arrest, chewing; stage 2, uni-
lateral or bilateral tonic movements/seizure; stage 3, rearing without falling; stage 4,
rearingwith falling, limbic seizures; stage 5, death. Ratings ofmotor seizures that occurred
concomitantly with strong EEG seizures were pooled for three days (days 3–5, days 6–8,
days 9–11) and summedup.Median seizure rating observedondays 9–11was signiﬁcant-
ly higher than that observed during days 3–5 (**p b 0.01, Kruskal-Wallis test with Mann–
Whitney post-hoc test).
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then with 10% normal horse serum (90 min, room temperature). As
primary antibody we used a mouse HDAC2 antibody (5113, Cell Signal-
ing Technology, Danvers, US) at a concentration of 1:2000 with over-
night incubation at room temperature. As secondary we used a
donkey anti mouse HRP antibody (715-036-151 from Jackson
ImmunoResearch; Dianova, Vienna) at a concentration of 1:500
(120 min, room temperature). The reaction product was intensiﬁed by
incubation with TSA Biotin (60 min, room temperature) followed by
staining with Nickel DAB (Drexel et al., 2012a). Western blotting re-
vealed that the antiserum detected equally HDAC1 and HDAC2 in the
mouse brain (not shown).
2.9. Quantitative evaluation of in situ hybridization autoradiograms
Quantitative evaluation was done on digitized images of the
autoradiographs (eight bit digitized image, 256 gray values) as
described previously (Tsunashima et al., 1997). Gray values were
measured using the public domain program ImageJ 1.38x (NIH, USA;
255 = white; 0 = black) and converted to relative optical density
(ROD). [14C]-micro-scales (Amersham Pharmacia Biotech, Amersham,
UK) were exposed together with the slides. They were used to obtain a
standard curve and to verify that RODvalueswerewithin the linear range.
2.10. Statistical analysis
We performed three independent experiments. They were ﬁrst
evaluated separately. Since no signiﬁcant differences were observed be-
tween individual experiments we pooled the %-values for each interval.
The total numbers of mice in the KA experimentwere: controls, 23; 2 h,
12; 4 h, 9; 6 h, 10; 12 h, 4; 24 h, 4; 48 h, 3; 7 days, 6; 14 days, 5; 28 days, 7
mice. In the pilocarpine experiment, the following numbers of mice
were used: Controls, 10; 4 h, 9; 24 h, 5; 28 d, 4 mice. ROD values were
calculated as % of the mean ROD of controls. Data are shown as
mean ± SEM. Statistical analysis was done using the GraphPad Prism
program (v 5.0d; GraphPad Software Inc., La Jolla, USA). In situ hybrid-
ization data were analyzed by one-way ANOVA with post-hoc Dunnetttest. Differences in ratings of motor seizures were analyzed using
Kruskal–Wallis test with Mann–Whitney post-hoc test.
3. Results
3.1. Intra-hippocampal KA model
3.1.1. EEG and behavioral data
We performed continuous telemetric EEG recordings until the mice
were killed; in 8 mice recordings were done for 28 days. Concomitantly
to EEG recordings video monitoring was performed in 12 mice for
14 days. In agreement with data published by (Bouilleret et al., 1999;
Fig. 3. Expression patterns ofmRNAs encoding class I HDACs 1–3 and8 aswell as class IVHDAC 11 in controlmice. The images represent photomicrographs of autoradiographs after in situ
hybridizationwith the respective radiolabeled antisenseprobes. Panels A–D, class I HDACs; panel F, class IVHDAC; panel E depicts a correspondingNissl staining taken from theAllen Brain
Atlas. GC, granule cell layer. Scale bar in F: 2 mm.
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by a trias of seizure-like events, the acute status epilepticus, frequent
hippocampal paroxysmal discharges (HPD) and rare spontaneous
strong seizures (Fig. 1).Fig. 4. Expression of class I HDAC1, 2, 3 and 8 and class IV HDAC11 mRNAs after unilateral inje
controls (Co) and at selected time points after KA injection after in situ hybridizationwith radiol
lacunosummoleculare) was injectedwith KA which is reﬂected by neurodegenerative changes
pression of HDAC1 throughout the ipsi- and contralateral hippocampus 4 h after KA; G, K: incre
24 h; N, O: decreased expression of HDAC8 in the ipsilateral (N) but increased expression in th
HDAC11 expression in the granule cell layer. Compare quantitative evaluation shown in Fig. 5.3.2. Status epilepticus
Although still deeply anesthetized, all KA-injectedmice developed a
status epilepticus seen in the EEG (Fig. 1A). At this time episodes ofction of KA into the hippocampus. Shown are photomicrographs of autoradiographs from
abelled antisense probes for the individualHDACs. The right CA1 sector (stratum radiatum/
in the CA1 and CA3 sectors of the right hippocampus. Arrows indicate: in B, decreased ex-
ased expression of HDAC2 (in G) and HDAC3 (in K) in the injected granule cell layer after
e contralateral (O) granule cell layer after 4 h and 12 h, respectively; R: early decrease in
Scale bar in T: 1 mm.
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frequency of these seizure spells progressed to continuous seizure
activity after 2 h. Thereafter continuous EEG discharges were observed
that started to become somewhat less frequent after 12 h and were
signiﬁcantly reduced in amplitude and frequency thereafter (Fig. 1A).
After 24 to 36 h the frequent status epilepticus-like discharges turned
into HPD (Fig. 1 C–D). Motor seizures were suppressed by the initial
anesthesia. Thus only rare mild motor convulsions were observed in
the video recordings.
3.3. Hippocampal paroxysmal discharges (HPD)
The spike/wave discharges seen during status epilepticus turned
into short paroxysmal discharges after 48 h characterized by short
periods of increased EEG-activity but without obvious behavioral
changes (Pallud et al., 2011). They were generally not preceded by
spike activity and revealed no postictal depression as observed after
spontaneous strong seizures (Fig. 1D and 1F). The mean rate of HPD
was 50.7 ± 3.30 per 24 h, the mean amplitude 0.77 ± 0.02 mV and
their mean duration 17.5 ± 0.50 s (n= 25). The number of HPD during
light (22.9 ± 4.99 per 12 h; n = 7) was not different from that during
dark (25.5 ± 5.61 per 12 h; n = 7). They were observed at the same
rate during the entire recording period (28 days).
3.4. Spontaneous strong seizures
About 48 h after KA injection, we observed rare strong seizures in
the EEGs of the continuously monitored mice in addition to the rather
frequent paroxysmal discharges. We monitored 224 spontaneous
strong seizures in 7 mice. They were characterized by a high-
amplitude EEG activity (1.4 ± 0.06 mV) lasting for more than 30 s
(45.0 ± 3.93 s), and – in contrast to HPD – were always followed by a
post-ictal ﬂattening of the EEG signal (Fig. 1D and F). Frequency of
strong seizures was 1.54 ± 0.14 per 24 h and they tended to occur
more frequently (not signiﬁcant) during night (0.85 ± 0.127 per 12 h;
n = 7) than during day (0.61 ± 0.084 per 12 h; n = 7).
3.5. Motor seizures
Motor seizures occurring concomitantly with strong EEG seizures
were rated in the video recordings. No changes in motor behavior
were observed concomitantly with HPD (number of observations: 50
in 7 mice). In total 60 spontaneous strong seizures were video-
analyzed for the concomitant behavioral correlate. Among all strong
EEG seizures 91.7% were accompanied by motor seizures of stages 1 to
4. During days 3 to 11 the severity of motor seizures monitored in
association with strong EEG seizures increased from median stage 2 at
days 3–5 to median stage 4 seizures at days 9 to 11 (Fig. 2; p b 0.01).
3.6. Histopathology
At all intervals investigated losses in CA1 and CA3 pyramidal
neurons and of interneurons were observed at the injection site as
early as 4 h after KA injection. At the early intervals (4 h to 12 h after
KA injection) the granule cell layer was not affected. At later intervals
we observed modest (24 h) and thereafter (after 14 and 28 days)
pronounced granule cell dispersion in the injected hippocampus as
reported previously (Haas et al., 2002; Riban et al., 2002; Pallud et al.,
2011) and shown by us elsewhere (Jagirdar et al., unpublished results).Fig. 5. Time course of changes in expression of class I HDACs (HDAC1, 2, 3 and 8) and class IVHD
mRNA expression as relative optic densities (ROD) expressed as % of controls (means ± SEM)
paring the injected (black bars) with the contralateral side (red bars). The right column show
injection side. The contralateral side is not affected by cell loss due to the local injection of K
14 days, 5; 28 days, 7. Statistical analysis was done by one-way ANOVA with Dunnett's post-hNo signs of histopathological changes were observed in the contralateral
hippocampus. Also no neurodegenerative changes were seen in other
brain areas such as the amygdala or entorhinal cortex.
3.7. Distribution of HDAC mRNAs in the control hippocampus
Fig. 3 shows the mRNA distribution of class I HDACs 1, 2, 3, 8
(Fig. 3A–D) and class IV HDAC11 (Fig. 3F) in the dorsal hippocampus
of control mice. HDAC mRNAs were well detected in the hippocampus
of control mice. Since the individual HDAC probes can bind at some-
what different afﬁnity a direct comparison of the extent of expression
between different HDAC mRNAs has to be judged with caution. The
expression patterns are clearly different between individual HDAC
species. Thus, whereas HDAC2, 3 and 11 mRNAs seem to be equally
distributed in all principal cell layers of the hippocampus, HDACs 1
and 8 are stronger expressed in the granule cells of the dentate gyrus
than in the Ammon's horn. We observed HDAC1, 2, 3 and 11 mRNA
expression also in other brain areas e.g., the cerebral cortex in the
same section (Fig. 3). The relative intensities of expression as well as
the distribution of individual HDAC mRNAs was in agreement to that
reported for the rat hippocampus recently (Broide et al., 2007) and
with the distribution of HDAC 2 protein shown by immunohistochem-
istry (Yao et al., 2013).
3.8. Changes in expression of Class I HDACs (HDAC1, 2, 3 and 8) after
intra-hippocampal KA injection
Images of HDAC mRNAs at different intervals after KA injection are
shown in Fig. 4. For considering also a possible local effect of the KA
injection, HDAC mRNA expression was analyzed in the granule cell
layers of the injected and of the contralateral hippocampus compared
to respective control values (Fig. 5 left column). In addition, changes
in the pyramidal layers contralateral to the KA injection, which were
not affected by neurodegeneration,were analyzed (Fig. 5 right column).
In contrast to changes seen in the expression of class II HDACs (Jagirdar
et al., unpublished results), changes in class I and IV mRNA levels were
rather similar in the ipsi- and contralateral granule cell layer and in the
contralateral pyramidal cell layers (Figs. 4, 5).
3.8.1. HDAC1
As shown in Figs. 4 and 5A, expression of class I HDAC1 mRNA
becomes markedly reduced 2, 4, 6 and 12 h after KA injection, both in
the ipsi- and in the contralateral granule cell layer (Figs. 4B, 5A; at 4 h:
23.8 ± 3.21%, p b 0.001; and 35.2 ± 3.68% of controls, p b 0.001, ipsi-
and contralateral to the injection, respectively). A trend for decreases
in HDAC1 mRNA levels was also observed in pyramidal cell layers at
the intervals 2 to 12 h after induction of the status epilepticus
(Figs. 4B, 5B; to 51 and 58% of control in CA1 and CA3, respectively;
not signiﬁcant). At this time continuous seizure activity was detected
in the EEG (Fig. 1A).
In the granule cell layers, HDAC1 mRNA levels recovered to control
values after 24 h and remained unchanged on both sides up to
28 days (except for the injected side after 14 days) (Figs. 4B, 5A). In con-
trast, in the contralateral pyramidal cell layers we observed pronounced
increases after 24 to 48 h (e.g., 48 h; CA1, 272.4 ± 49.94%, p b 0.001;
CA3, 382.6 ± 34.47% of control, p b 0.001). Thereafter HDAC1 mRNA
levels returned to control values also in the pyramidal cell layers, except
for 57 and 63% increases in sectors CA3 after 14 days and in sector CA1
after 28 days, respectively (Figs. 4C, D, 5B). Behaviorally, the initialAC11 after unilateral injection of KA into thehippocampus. Theﬁgures showchanges in the
. The left column depicts changes in mRNA expression in the granule cell layer (GC) com-
s changes in the pyramidal layers (green bars, CA1; brown bars, CA3) contralateral to the
A. N numbers: Controls, 23; 2 h, 12; 4 h, 9; 6 h, 10; 12 h, 4; 24 h, 4; 48 h, 3; 7 days, 6;
oc test. *p b 0.05, **p b 0.01, ***p b 0.001 vs. controls.
Fig. 6.Time course of expression of HDAC2 immunoreactivity afterKA-induced seizures. HDAC2-IRwas primarily seen inneurons and rarely in astrocytes. Note the slight general reduction
in IR in the contralateral hippocampus (therewasnoneurodegeneration) after 4 h (E, F; blue arrow).Note the strongly increased expression of the protein in sector CA1 of the contralateral
hippocampus 12 and 24 h after KA (blue arrows in I and C, but also on the injected side, D). Interestingly, 12 h after KA therewas an entire loss of the protein in dentate granule cells, both
on the injected and on the contralateral side (red arrows in I, J). After 14 daysHDAC2protein recovered in all principal cells. Note the beginning of granule cell dispersion (blue arrow inH).
There seemed to be also some expression in astrocytes in the hilus of the injected dentate gyrus (Fig. 8L). In some instances wide-spread labeling of glia was observed in the injected hip-
pocampus at later intervals (28 d after KA injection; not shown). We have no proof yet whether this labeling is speciﬁc. Scale bars: 200 μm in H for A–H; 60 μm in L, for K, L.
Fig. 7. Expression of HDAC 1, 2, 3, 8 mRNAs after pilocarpine-induced status epilepticus. Shown are photomicrographs of autoradiographs after in situ hybridization with radiolabelled
antisense probes for the individual HDACs of controls (Co) and selected time points after pilocarpine injection (4 h and 28 days). Arrows indicate: in B, decreased expression of HDAC1
in the dentate granule cell layer and in the hippocampal pyramidal cell layer 4 h after pilocarpine; E: decreased expression of HDAC2; K, L, decreased expression of HDAC8 4 h and
28 days after KA. Compare quantitative evaluation shown in Fig. 8. Scale bar in L: 500 μm.
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Fig. 8. Time course of changes in expression of HDAC 1, 2, 3, 8 and 11 mRNAs after pilocarpine-induced status epilepticus. The ﬁgures show changes in the mRNA expression as relative
optic densities (ROD) expressed as % of controls (means± SEM). Black bars represent granule cell (GC)mRNA, green and brown bars pyramidal cell layers of sectors CA1 and CA3, respec-
tively. Numbers ofmice: Controls, 10; 4 h, 9; 24 h, 4; 28 days, 7. Statistical analysiswas doneby one-wayANOVAwith Dunnett's post-hoc test. *p b 0.05, **p b 0.01, ***p b 0.001 vs. controls.
100 R. Jagirdar et al. / Experimental Neurology 273 (2015) 92–104status epilepticus (seen in the EEG) faded away 12 to 24 h after KA and
the interval thereafter was characterized by 1 to 2 spontaneous strong
EEG-seizures per day (Fig. 1).
3.8.2. HDAC2
Also HDAC2 mRNA expression was signiﬁcantly reduced in granule
cells on both sides 2 to 4 h after KA injection (Fig. 5C). In contrast to
HDAC1, HDAC2 mRNA levels were then signiﬁcantly increased 12 h
after KA contralateral to the KA injection (Fig. 5C; 159.6 ± 6.66% of
controls, p b 0.001), after 24 h in both granule cell layers (Figs. 4G, 5C;
ipsilateral to KA injection: 136.7± 11.69% of controls, p b 0.001; contra-
lateral, 154.7 ± 5.02%, p b 0.001) and approached control values after
48 h. HDAC2 mRNA levels were again increased in the granule cell
layer of the contralateral hippocampus after 14 days (Figs. 4H, 5C;
142.9 ± 5.78% of controls, p b 0.001) and bilaterally after 28 days
(Fig. 5C; ipsilateral: 115.6 ± 2.98%, p b 0.05; contralateral: 133.2 ±
5.34% of controls, p b 0.001).
In sectors CA1 and CA3 of the pyramidal cell layer changes in HDAC2
mRNA levels were characterized by modest decreases (by about 10 to
15%) 4 and 6 h (Figs. 4F, 5D; signiﬁcant for CA3, p b 0.05) after KA injec-
tion and by small increases (Figs. 4G, 5D; CA1, 122.7± 0.78% of control;
p b 0.01) after 24 h.We observed also modest increases in sector CA3 at
the late intervals after 14 and 28 days (Fig. 5D).
3.8.3. HDAC3
In contrast to the prominent changes seen forHDACs 1 and 2,HDAC3
mRNA was not signiﬁcantly changed in the granule cell layers at theearly intervals (2 to 12 h after KA). It revealed, however, signiﬁcant in-
creases in its levels at 24 (Fig. 5E; 139.8 ± 10.60% of control; p b 0.01)
and 48 h intervals (163.4 ± 12.39% of control; p b 0.001) in the granule
cell layer of the contralateral hippocampus (Fig. 5E). In pyramidal layers
CA1 and CA3 (contralateral to KA injection), HDAC3 mRNA expression
paralleled that in the contralateral granule cell layer with signiﬁcant in-
creases after 24 (Figs. 4K, 5E; CA1: 140.0 ± 9.84% of control, p b 0.01;
CA3: 138.5 ± 13.10%, p b 0.05) and 48 h (Fig. 5F; CA1, 151.7 ± 11.30%
of control, p b 0.001; CA3: 147.9 ± 23.25%, p b 0.01) that returned to
control levels thereafter (Fig. 5E, F).3.8.4. HDAC8
HDAC8was only weakly expressed. The quantitative evaluation was
done only in one of three experiments covering the time points 4, 12, 24
and 48 h and 14 days after KA injection (Fig. 5G, H). At the 4 h interval
we observed a 53.3 ± 8.25% (p b 0.05) and 34.7 ± 8.73% (not signiﬁ-
cant) decrease of HDAC8mRNA levels in the ipsilateral and contralater-
al granule cell layers, respectively (Figs. 4N, 5G). Twelve and 24 h after
KA injection HDAC8 mRNA levels were markedly increased in the
contralateral granule cell layer, statistically signiﬁcant for the 12 h
interval (160.4 ± 19.27% p b 0.05) (Figs. 4O, 5G).
Similarly as for HDAC3, 12 to 48h after KA in contralateral pyramidal
cell layers of sectors CA1 and CA3 up to 60 and 86% increased HDAC8
mRNA levels were observed, respectively. Due to the small sample
size in the experiment the numbers are, however, statistically not signif-
icant (Fig. 5H).
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HDAC11 mRNA is prominently expressed throughout the entire
hippocampus (Figs. 3, 4Q). Its levels were dramatically decreased (by
35.4% to 93.8%; P-values 0.05 to 0.001) throughout the entire hippocam-
pus (granule cell and pyramidal cell layers) 6 to 24 h after unilateral KA
injection (Figs. 4R, S, 5I, J). They recovered rapidly thereafter and were
similar to control levels 2 to 28 days after KA injection (Figs. 4T, 5I). In
the dentate gyrus the early decreasesmostly exceeded 75% and reached
more than 93% in the granule cell layer of the injected hippocampus
after 12 and 24 h (Fig. 5I; 12 h: granule cell layer: ipsilateral, 6.1 ±
5.53% of control, p b 0.001; contralateral: 33.2 ± 16.32% of control, p b
0.01). In the pyramidal cell layer of sectors CA1 and CA3 decreases in
HDAC11mRNA levelswere 40 to 70%between 4 and24h after KA injec-
tion (Fig. 5J; e.g., 24 h: CA1, 30.2 ± 18.65% of control, p b 0.001; CA3,
27.4 ± 17.26% of control, p b 0.05).
3.10. Changes in HDAC protein after intra-hippocampal injection of KA
To verify the observed changes in the expression of HDACmRNAs on
the protein level we attempted to perform immunohistochemistry. We
ﬁrst tested several antibodies by western blotting and observed for
most of them several unspeciﬁc bands and obtained low quality
immune histochemical labeling. The comparatively high concentration
of HDAC2 protein and two valuable antibodies (antibody 5223 from
Cell Signaling and ab51823 from Abcam) then allowed clear detection
of HDAC2.
As shown in Fig. 6A, B, HDAC2 is highly expressed in nuclei of
neurons. Its distribution in the hippocampus follows that of its mRNA
distribution (Fig. 3). Rarely HDAC2-immunoreactivity (IR) was also
seen in astrocytes. Taken the contralateral hippocampus (there was no
neurodegeneration) we observed a slight general reduction in HDAC2-
IR (Fig. 6E, F). This was contrasted by a pronounced increased
expression of the protein in sector CA1 of the contralateral hippocam-
pus 12 and 24 h after KA injection (Fig. 6I, C, but also D). Interestingly
12 h after KA injection there was an entire loss of the protein in dentate
granule cells, both on the injected and on the contralateral side (Fig. 6I,
J). After 14 d HDAC2 protein had recovered in all principal cells. HDAC2-
IR indicated expression of the protein in astrocytes of the dentate hilus
of injected hippocampus (Fig. 6L) In some instances wide-spread
labeling of glia was observed in the injected hippocampus at later
intervals (28 days after KA injection; not shown). We have no proof
yet whether this labeling is speciﬁc.
3.11. Pilocarpine model
3.11.1. Behavior and neuropathology
In order to separate changes of HDAC expression that are due to
seizure activity and epileptogenesis from those that are generated by
stimulation of KA receptors we investigated the expression of HDAC
mRNAs also in the pilocarpinemodel of epilepsy. As described by before
(Cavalheiro et al., 1996; Pitsch et al., 2007), pilocarpine induced a status
epilepticus characterized by tonic-clonic seizures and full limbic convul-
sions with rearing and falling over in all mice investigated. The status
epilepticus was interrupted by injection of diazepam 45 min after the
ﬁrst limbic seizure. We performed no EEG recordings in these mice.
Histopathological changes were characterized by (20–40%) loss of CA1
and CA3 pyramidal neurons seen at the 24 h and 28 day intervals.
3.11.2. Expression of HDAC mRNAs in the pilocarpine model of TLE
Also in the pilocarpine model of TLE changes in the expression of
individual HDACs followed distinctly different patterns, both in the re-
gional expression and in the temporal patterns. In contrast to our ﬁnd-
ings after intra-hippocampal KA injection, changes in the individual
HDAC transcripts after pilocarpine-induced status epilepticus were
similar in different hippocampal subﬁelds.3.11.3. Class I HDAC 1, 2, 3 and 8 mRNAs
As shown in Figs. 7 and 8, mRNA levels of class I HDACs 1, 2, 3 and 8
were decreased in the pyramidal cell layer of sector CA1 and in dentate
granule cells during the status epilepticus at 4 h after pilocarpine injec-
tion. These decreases were more pronounced for HDAC1, 2 and 8
mRNAs (by 25 to 70%) than for HDAC3 (20 to 30%) (Figs. 7B, E, H, K,
8A–D; granule cell layer: HDAC1, 31.2 ± 3.81% of control, p b 0.001;
HDAC2, 74.8 ± 5.87% of control, p b 0.01; HDAC3, 79.1 ± 3.91% of con-
trol, p b 0.01; HDAC8, 54.4 ± 5.95% of control, p b 0.01). No changes
were observed in HDAC3 and 8 mRNA expression at the 4 h interval in
the pyramidal cell layer of sector CA3. After 24 h, HDAC2, 3 and 8
mRNA levels had returned to control values but, interestingly, increased
for HDAC1 in the pyramidal cell layer (Fig. 8A; CA3: 197.0 ± 23.90% of
control, p b 0.001). At the late interval, 28 days after the initial status
epilepticus, HDAC1 mRNA levels tended to increase (not signiﬁcant)
in the sectors CA1 and CA3, whereas those of HDAC2 tended to decrease
(signiﬁcant only for sector CA1). HDAC3 and HDAC8 mRNA levels were
signiﬁcantly decreased in all principal cell layers of the hippocampus by
25 to 50% and 40 to 85%, respectively (Fig. 8C, D).
3.11.4. Class IV HDAC 11 mRNA
HDAC11 mRNA levels were not signiﬁcantly altered, although there
was a tendency for a decrease in the granule cell layer (by about 35%) at
the 4 h interval, and in CA1 pyramidal and in the granule cells after
28 days (Fig. 8E).
4. Discussion
4.1. Seizure behavior of mice after unilateral intra-hippocampal injection of
KA
Changes in the EEG were similar as previously reported (Bouilleret
et al., 1999; Riban et al., 2002; Pallud et al., 2011). They were character-
ized by a trias of epilepsy-like events, 1) the acute status epilepticus,
2) frequent HPD and 3) rare spontaneous strong seizures reﬂecting
manifest epilepsy in the mice. All three events appear to be generated
in the hippocampus, respectively the dentate gyrus (Pallud et al.,
2011). Continuous telemetric recordings used in our study allowed a
further characterization of their onset and frequency. Interestingly,
based on EEG-recordings the initial KA-induced status epilepticus lasted
about 4 to 24 h and was most severe after around 4 to 8 h although be-
havioral seizures were modest and rare. It was followed by frequent
HPD (around 50 per 24 h) observed during the entire 28 day recording
period. Strong spontaneous seizures were considerably less frequent
(around 1.5 per 24 h). In contrast to other TLE models (Drexel et al.,
2012b) the onset of spontaneous strong seizures was uniform and fast
(already 3 days after KA). An interesting ﬁnding was that strong EEG-
seizures were initially accompanied primarily by stage 2 behavioral sei-
zures (median) and they rapidly (at days 9 to 11) developed to full
motor seizures (median 4). This different interval between onset of
strong EEG seizures and of full motor seizures may be part of a rather
brief period of epileptogenesis. It may relate also to the expression
patterns of some HDAC mRNAs that were distinctly different at the 24
to 48 h interval.
4.2. Early changes in HDAC mRNA expression during acute KA-induced
status epilepticus
Notably the class I HDACs, HDAC1 and 2 were down-regulated on
both sides in the dentate gyrus 2 to 6 h after KA injection and in sectors
CA1 and CA3 after 4 and 6 h. This was paralleled by even more
prominent down-regulation of class IV HDAC11 in dentate granule
cells and hippocampal pyramidal cells. Interestingly, changes in IR did
not entirely match changes in mRNA expression of HDAC2. There was
a general decrease inHDAC2protein in the hippocampusduring the sta-
tus epilepticus reﬂecting that in mRNA expression. With some delay,
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the granule cell layers of both sides when mRNA levels recovered al-
ready there. The subsequently increased expression in the pyramidal
cell layer and the recovery and modest increases in all principal layers
after 14 days was similar on protein and mRNA level. These changes
may be clearly related to the acute generalized EEG seizures during
the status epilepticus. Strikingly, these rapid decreases in HDAC mRNA
levels were restricted to class I and IV HDACs; they were not seen for
class IIa and IIb mRNAs (Jagirdar et al., unpublished results). Early
changes in the pilocarpine model were very similar to those in the
kainate model, especially in respect to the pronounced decreases in
HDAC1, 2 and 8 mRNA expression in all hippocampal subﬁelds during
the status epilepticus (4 h) although the early decrease in HDAC2
mRNA levels seen in all principal layers of the hippocampus after
pilocarpine were not seen in the KA model.
Decreased mRNA levels have been suggested to occur in the course
of status epilepticus due to the marked activation of transcription
(Wasterlain, 1972). Here we observe decreases in individual HDAC
mRNAs (HDAC1, and 11) but not in HDAC3 mRNA. HDAC5 mRNA ex-
pression is even increasing at the same time (Jagirdar et al., unpublished
results). The decreased expression of class I HDACs in both seizure
models coincides with the previously reported hyperacetylation of
histone H4 at c-fos and c-jun promoters and increased c-fos and c-jun
expression 0.5 to 3 h after a status epilepticus induced by i.p. KA
injection in mice (Sng et al., 2006). Six h after KA injection, acetylated
histones approached control levels again. Acetylated H4 co-
precipitatedwith c-fos and c-junDNA and thereforemay have facilitated
the observed increases in immediate early gene expression. Pretreat-
ment with the histone acetyltransferase inhibitor curcumin suppressed
H4 acetylation, c-fos and c-jun expression and acute seizure activity
(Sng et al., 2006). These experiments clearly indicate a role of gene
products expressed upon H4 acetylation. The fast decreases in class I
HDAC expression in our KA and pilocarpine treated mice may contrib-
ute to the increased levels of hyperacetylated H4. This is supported by
the fact that treatment with the HDAC inhibitor trichostatin A also
augments c-fos and c-jun expression both in control rats and after
KA-induced status epilepticus (Sng et al., 2005). Like H4 acetylation
also down-regulation of class I HDACs (in our experiments) was
transient indicating a possible causative relationship of the initial
decrease in class I HDAC expression and the hyperacetylation of H4.
Consequences of seizure-induced changes in H4 acetylation,
however, highly depend on the individual promoter involved. Thus, ex-
pression of brain derived neurotrophic factor (BDNF) is rapidly induced
in granule cells and pyramidal cells of the hippocampus after experi-
mentally induced status epilepticus in rats (Isackson et al., 1991;
Dugich-Djordjevic et al., 1992). Interestingly, seizure-induced H4
acetylation may be differently affected at different BDNF promoters
(Huang et al., 2002). Downstream promoters (P1 and P2) for splice
variants 1 and 2 are associatedwith hyperacetylatedH4whereas theup-
stream P4 promoter (corresponding to splice variant 4) co-precipitated
with hypoacetylated H4 three hours after pilocarpine-induced status
epilepticus. This indicates that differential histone H3 and H4 acetyla-
tion/deacetylation at different promoters of the same genemay regulate
expression of different BDNF splice variants upon epileptic seizures
(Timmusk et al., 1993; Huang et al., 2002; Tsankova et al., 2004).
BDNF splice variants appear to be differently targeted into different
subcellular compartments of hippocampal principal neurons, such as
soma, dendrites or axons (Chiaruttini et al., 2008) and over-expression
of BDNF may exert both pro- and anti-convulsive/-epileptogenic actions
(Simonato et al., 2006).
Besides transient overexpression of BDNF and of immediate early
genes c-fos and c-jun (Dragunow and Robertson, 1987) acute seizures
increase gene expression of numerous neuropeptides and proteins as-
sociated e.g.,with inﬂammation, neurodegeneration, neuronal plasticity
or neurotransmission (Forstermann et al., 1982; Sperk, 1994; Gorter
et al., 2006; Vezzani et al., 2011). Decreased expression of HDACs maybe onemechanism facilitating expression of these genes. The respective
gene products may support pro-convulsive (Forstermann et al., 1982)
or endogenous anticonvulsive mechanisms (Sperk et al., 1992;
Esclapez and Houser, 1999; Szabo et al., 2000). Thus, increased expres-
sion of the T-type calcium channelα1-subunit Cav3.2 after pilocarpine-
induced status epilepticus leads to increased cellular T-type Ca++
currents and an increase in intrinsic burst ﬁring. Since these functional
changes are absent in Cav3.2 knock out mice they may represent a
speciﬁc seizure-promoting mechanism (Becker et al., 2008).
In contrast, treatmentwith the anticonvulsive class I HDAC inhibitor
valproic acid increases expression of neuropeptide Y in the reticular nu-
cleus thalami of rats suggesting that the expression of neuropeptide Y
may be under the control of HDACs (Brill et al., 2006). Neuropeptide Y
becomes over-expressed by recurrent seizures and represents a potent
endogenous anticonvulsive principle (Vezzani and Sperk, 2004). Thus,
down-regulation of HDACs may lead to an anticonvulsive effect by in-
creasing neuropeptide Y expression in the same way as their inhibition
by treatment with valproic acid.4.3. Transient up-regulation of class I HDACs 12 to 48 h after seizures
induced by intrahippocampal injection of KA
Subsequent to their pronounced down-regulation, class I HDACs 1, 2
and 3 were signiﬁcantly up-regulated in the contralateral granule cell
and pyramidal cell layers 24 and 48 h after KA injection. This ﬁnding is
consistent with increased expression of HDAC2 protein in the temporal
neocortex of patients with temporal lobe epilepsy and in the dentate
gyrus of rats in acute (1 day) and chronic phase (60 days) after
lithium/pilocarpine induced status epilepticus (Huang et al., 2012;
Chen et al., 2013).
The changes in HDAC expression could be merely counter-
regulation of their preceding down-regulation and interrupt or even
reverse the increased gene expression of the corresponding proteins
and peptides. Increased expression of HDACs may lead to decreased
expression of certain genes and thereby promote epileptogenesis.
Thus, expression of the AMPA receptor subunit GluA2 is suppressed in
animal models of epilepsy resulting in potent pro-convulsive effects
(Grooms et al., 2000; Gorter et al., 2006). Decreased expression of the
AMPA receptor subunit GluA2 (but not of GluA1) after KA induced sei-
zures leads to GluA2 lacking AMPA receptors revealing increased Ca++
inﬂux upon stimulation and thus increased vulnerability to seizure
propagation and excitotoxic brain damage (Grooms et al., 2000;
Gorter et al., 2006). Huang et al. (2002) reported decreased acetylation
of the H4 histone at the GluA2 promoter in the hippocampal CA3 sector
as early as 3 h after pilocarpine-induced status epilepticus. Also these
experiments indicate a role of histone acetylation/deacetylation. In our
experiments up-regulation of HDACs 1 to 3 in granule cell and pyrami-
dal cell layers occurred at a somewhat later interval (12 to 24 h after KA
injection). As shown elsewhere (Jagirdar et al., unpublished results) we
observed up-regulation of class II HDAC5 in granule and pyramidal cell
layers already 4 to 6 h lasting up to 12 and 48 h after KA injection. Thus
in principle increased expression of class I HDACs and of class II HDAC5
could be responsible for the reduced acetylation of histone H4 at the
GluA2 promoter and for reduced GluA2 expression. Interestingly,
the HDAC inhibitor trichostatin A prevented and quickly reversed
deacetylation of GluA2-associated histones (Huang et al., 2002).
Trichostatin A also blunted seizure-induced downregulation of GluA2
mRNA in CA3 indicating a mechanism on the level of histone
deacetylation rather than decreased activity of histone acetyltransfer-
ases. Also decreased expression of GABAA receptor subunits δ and α5
after KA and pilocarpine-induced status epilepticus, mediating tonic
inhibition, may contribute to epileptogenesis (Schwarzer et al., 1997;
Tsunashima et al., 1997; Peng et al., 2004; Drexel et al., 2013). These
changes in the constitution of GABAA receptors are, however, not
transient but long lasting.
103R. Jagirdar et al. / Experimental Neurology 273 (2015) 92–104There was an obvious difference between the kainate and the
pilocarpine models in respect to the up-regulation of HDACs 1 to 3 at
the 24 h interval. It was clearly seen in the KA model but not after
pilocarpine injection. Interesting is also the transient nature of this
effect. The most likely explanation is that we did not pick up changes
in the pilocarpine model due to a slightly different time course of
seizure induced changes in HDAC expression. Whereas we investi-
gated the 24 h and 48 h intervals after KA injection we examined it
only 24 h after pilocarpine injection. It is noteworthy that the process
of epileptogenesis appears to be faster in the KAmodel. Spontaneous
strong EEG seizures occurred already after 3 days and were associat-
ed with full motor seizures between 6 and 11 days. In contrast, in the
mouse pilocarpine model development of spontaneous strong EEG
seizures lasts between 4 and 42 days (Cavalheiro et al., 1996). Thus
it may be that if increased expression of HDACs is related to
epileptogenesis it may occur at different intervals in the KA and
pilocarpine models.
Changes in the expression of HDACs may, however, also induce
different epilepsy-related changes, such as apoptosis, neuronal sprouting,
or regulation of axon formation resulting in different cognitive or
neuropsychological changes observed in TLE. Thus, overexpression
of HDAC2, but not of HDAC1, decreases dendritic spine density,
synapse number, and synaptic plasticity in the CA1 sector of the hip-
pocampus as well as memory formation in mice (Guan et al., 2009).
Conversely, HDAC2 knock out results in increased synapse number
and memory facilitation, similar to chronic treatment with HDAC
inhibitors in mice. And, the reduced synapse number and learning
impairment of HDAC2 overexpressing mice can be ameliorated by
chronic treatment with HDAC inhibitors (Guan et al., 2009). In
contrast, viral vector-induced overexpression of HDAC1 in the
hippocampus of mice had no effect on short- and long-term memory
acquisition but promoted contextual fear extinction (Bahari-Javan
et al., 2012). Increases in HDAC1 and 2 expression, however, were
transient at the 24 to 48 h intervals after KA injection and thus may
not substantially inﬂuence the neuropsychological behavior of the
epileptic mice. Less prominent increases in HDAC1 and 2 mRNA levels
were also observed at the late intervals (14 and 28 days after KA injec-
tion). Theymay be related to cognitive and neuropsychological changes
observed in chronically epilepticmice, including impaired spatial mem-
ory and decreased anxiety (Chauviere et al., 2009; Jones et al., 2009).
The functional consequence (epilepsy?) of these increases in HDAC
expression may be experimentally counteracted by HDAC inhibition
e.g., with valproic acid.4.4. Long-time changes in HDAC expression in TLE models
Main ﬁndings at the 14 and 28 d intervals were a signiﬁcant
up-regulation of HDAC1 and 2 mRNAs in the KA model and down-
regulation of HDACs 3 and 8 in the pilocarpine model. Both changes
were statistically signiﬁcant and may relate the chronic epileptic
state in these animals. Since these changes are distinctly different
in the twomodels they argue also for differences in their pathophys-
iology. Major differences between the twomodels are the frequentHPD
and the granule cell dispersion observed after intra-hippocampal
kainate but not after pilocarpine. How these could relate to the
observed differences in HDAC expression will require further
investigations.
In conclusion, our data demonstrate pronounced and distinctively
different changes in the expression of class I and IV HDACs in subﬁelds
of the hippocampus after an acute status epilepticus, during
epileptogenesis and in chronic TLE. They suggest a crucial role of gene
expression of HDACs in the epigenetic regulation of seizure-induced
expression of neuropeptides and proteins and thereby promote the
development of epilepsy as well as the formation of endogenous
anticonvulsive mechanisms.5. Limitations of our study
Our study concentrated on patterns of the expression of HDACs on
the mRNA level. It is rather descriptive and with the exception of
HDAC2wehave no indication yetwhether presumed changes in protein
expression follow that ofmRNA levels. Also the link to functional chang-
es affecting regulation of expression of different proteins and their role
in epileptogenesis is of course missing. This was far beyond the aim of
this initial unbiased approach. Since there is a clear balance between
the actions of histone acetyl transferases and HDACs, knowledge on
epilepsy-related changes in the expression of histone acetyl transferases
would be as pertinent as that for HDACs. HDACs may, however, act also
on other targets than on histones, notably on cytoplasmatic proteins.
We address this question in a submitted manuscript (Jagirdar, unpub-
lished). On the other hand we refer to a variety of studies indicating
changes in the acetylation state of speciﬁc promoters of genes presum-
ably related to epileptogenesis (e.g., Huang et al., 2012; Chen et al.,
2013). This gives clear indication for the relevance of the observed
dynamic changes in HDAC mRNA expression. A direct link of the here
described changes in the expression of HDACs to these epigenetic
mechanisms, however, has still to be corroborated.
Acknowledgments
We thank Anneliese Bukovac and Elisabeth Gasser for technical
assistance and Dr. Heide Hörtnagl for proof reading the manuscript.
The work was supported by the European Science Foundation
(Eurocores Programme; EuroEPIGENOMICS) and the Austrian Research
Fund (Project I 664).
References
Babb, T.L., Lieb, J.P., Brown, W.J., Pretorius, J., Crandall, P.H., 1984. Distribution of pyrami-
dal cell density and hyperexcitability in the epileptic human hippocampal formation.
Epilepsia 25, 721–728.
Bahari-Javan, S., Maddalena, A., Kerimoglu, C., Wittnam, J., Held, T., Bahr, M., Burkhardt, S.,
Delalle, I., Kugler, S., Fischer, A., Sananbenesi, F., 2012. HDAC1 regulates fear
extinction in mice. J. Neurosci. 32, 5062–5073.
Becker, A.J., Pitsch, J., Sochivko, D., Opitz, T., Staniek, M., Chen, C.C., Campbell, K.P., Schoch,
S., Yaari, Y., Beck, H., 2008. Transcriptional upregulation of Cav3.2 mediates
epileptogenesis in the pilocarpine model of epilepsy. J. Neurosci. 28, 13341–13353.
Bouilleret, V., Ridoux, V., Depaulis, A., Marescaux, C., Nehlig, A., Le Gal La Salle, G., 1999.
Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate
injection in adult mice: electroencephalography, histopathology and synaptic reorga-
nization similar to mesial temporal lobe epilepsy. Neuroscience 89, 717–729.
Brill, J., Lee, M., Zhao, S., Fernald, R.D., Huguenard, J.R., 2006. Chronic valproic acid
treatment triggers increased neuropeptide y expression and signaling in rat nucleus
reticularis thalami. J. Neurosci. 26, 6813–6822.
Broide, R.S., Redwine, J.M., Aftahi, N., Young, W., Bloom, F.E., Winrow, C.J., 2007. Distribu-
tion of histone deacetylases 1–11 in the rat brain. J. Mol. Neurosci. 31, 47–58.
Cavalheiro, E.A., Santos, N.F., Priel, M.R., 1996. The pilocarpine model of epilepsy in mice.
Epilepsia 37, 1015–1019.
Chauviere, L., Rafraﬁ, N., Thinus-Blanc, C., Bartolomei, F., Esclapez, M., Bernard, C., 2009.
Early deﬁcits in spatial memory and theta rhythm in experimental temporal lobe
epilepsy. J. Neurosci. 29, 5402–5410.
Chen, Y., Xie, Y., Wang, H., Chen, Y., 2013. SIRT1 expression and activity are up-regulated
in the brain tissue of epileptic patients and rat models. Nan Fang Yi Ke Da Xue Xue
Bao 33, 528–532.
Chiaruttini, C., Sonego, M., Baj, G., Simonato, M., Tongiorgi, E., 2008. BDNF mRNA splice
variants display activity-dependent targeting to distinct hippocampal laminae. Mol.
Cell. Neurosci. 37, 11–19.
Chuang, D.M., Leng, Y., Marinova, Z., Kim, H.J., Chiu, C.T., 2009. Multiple roles of HDAC
inhibition in neurodegenerative conditions. Trends Neurosci. 32, 591–601.
Clynen, E., Swijsen, A., Raijmakers, M., Hoogland, G., Rigo, J.M., 2014. Neuropeptides as
targets for the development of anticonvulsant drugs. Mol. Neurobiol. 50, 626–646.
Dragunow, M., Robertson, H.A., 1987. Kindling stimulation induces c-fos protein(s) in
granule cells of the rat dentate gyrus. Nature 329, 441–442.
Drexel, M., Kirchmair, E.,Wieselthaler-Holzl, A., Preidt, A.P., Sperk, G., 2012a. Somatostatin
and neuropeptide Y neurons undergo different plasticity in parahippocampal regions
in kainic acid-induced epilepsy. J. Neuropathol. Exp. Neurol. 71, 312–329.
Drexel, M., Preidt, A.P., Sperk, G., 2012b. Sequel of spontaneous seizures after kainic
acid-induced status epilepticus and associated neuropathological changes in the
subiculum and entorhinal cortex. Neuropharmacology 63, 806–817.
Drexel, M., Kirchmair, E., Sperk, G., 2013. Changes in the expression of GABAA receptor
subunit mRNAs in parahippocampal areas after kainic acid induced seizures. Front
Neural Circuits 7, 142.
104 R. Jagirdar et al. / Experimental Neurology 273 (2015) 92–104Dugich-Djordjevic, M.M., Tocco, G., Lapchak, P.A., Pasinetti, G.M., Najm, I., Baudry, M.,
Hefti, F., 1992. Regionally speciﬁc and rapid increases in brain-derived neurotrophic
factor messenger RNA in the adult rat brain following seizures induced by systemic
administration of kainic acid. Neuroscience 47, 303–315.
Esclapez, M., Houser, C.R., 1999. Up-regulation of GAD65 and GAD67 in remaining hippo-
campal GABA neurons in a model of temporal lobe epilepsy. J. Comp. Neurol. 412,
488–505.
Fisher, P.D., Sperber, E.F., Moshe, S.L., 1998. Hippocampal sclerosis revisited. Brain Dev. 20,
563–573.
Forstermann, U., Heldt, R., Knappen, F., Hertting, G., 1982. Potential anticonvulsive prop-
erties of endogenous prostaglandins formed inmouse brain. Brain Res. 240, 303–310.
Franklin, K.B.J., Paxinos, G., 2008. The Mouse Brain in Stereotaxic Coordinates. Elsevier,
Amsterdam.
Furtinger, S., Pirker, S., Czech, T., Baumgartner, C., Ransmayr, G., Sperk, G., 2001. Plasticity
of Y1 and Y2 receptors and neuropeptide Y ﬁbers in patients with temporal lobe ep-
ilepsy. J. Neurosci. 21, 5804–5812.
Gass, P., Herdegen, T., Bravo, R., Kiessling, M., 1992. Induction of immediate early gene
encoded proteins in the rat hippocampus after bicuculline-induced seizures: differ-
ential expression of KROX-24, FOS and JUN proteins. Neuroscience 48, 315–324.
Gorter, J.A., van Vliet, E.A., Aronica, E., Breit, T., Rauwerda, H., Lopes da Silva, F.H.,
Wadman, W.J., 2006. Potential new antiepileptogenic targets indicated bymicroarray
analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 26, 11083–11110.
Grooms, S.Y., Opitz, T., Bennett, M.V., Zukin, R.S., 2000. Status epilepticus decreases gluta-
mate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before
neuronal death. Proc. Natl. Acad. Sci. U. S. A. 97, 3631–3636.
Guan, J.S., Haggarty, S.J., Giacometti, E., Dannenberg, J.H., Joseph, N., Gao, J., Nieland, T.J.,
Zhou, Y., Wang, X., Mazitschek, R., Bradner, J.E., DePinho, R.A., Jaenisch, R., Tsai, L.H.,
2009. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature
459, 55–60.
Haas, C.A., Dudeck, O., Kirsch, M., Huszka, C., Kann, G., Pollak, S., Zentner, J., Frotscher, M.,
2002. Role for reelin in the development of granule cell dispersion in temporal lobe
epilepsy. J. Neurosci. 22, 5797–5802.
Holliday, R., Pugh, J.E., 1975. DNA modiﬁcation mechanisms and gene activity during
development. Science 187, 226–232.
Houser, C.R., 1990. Granule cell dispersion in the dentate gyrus of humans with temporal
lobe epilepsy. Brain Res. 535, 195–204.
Huang, Y., Doherty, J.J., Dingledine, R., 2002. Altered histone acetylation at glutamate
receptor 2 and brain-derived neurotrophic factor genes is an early event triggered
by status epilepticus. J. Neurosci. 22, 8422–8428.
Huang, Y., Zhao, F., Wang, L., Yin, H., Zhou, C., Wang, X., 2012. Increased expression of
histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and
rat models. Synapse 66, 151–159.
Hwang, J.Y., Aromolaran, K.A., Zukin, R.S., 2013. Epigenetic mechanisms in stroke and
epilepsy. Neuropsychopharmacology 38, 167–182.
Isackson, P.J., Huntsman, M.M., Murray, K.D., Gall, C.M., 1991. BDNF mRNA expression is
increased in adult rat forebrain after limbic seizures: temporal patterns of induction
distinct from NGF. Neuron 6, 937–948.
Jones, N.C., Kumar, G., O'Brien, T.J., Morris, M.J., Rees, S.M., Salzberg, M.R., 2009. Anxiolytic
effects of rapid amygdala kindling, and the inﬂuence of early life experience in rats.
Behav. Brain Res. 203, 81–87.
Khorasanizadeh, S., Ostankovitch, M., 2014. Zooming into epigenetic regulatory elements
in health and disease. J. Mol. Biol. 426, 3327–3329.
Kimura, A., Matsubara, K., Horikoshi, M., 2005. A decade of histone acetylation: marking
eukaryotic chromosomes with speciﬁc codes. J. Biochem. 138, 647–662.
Kobow, K., Blumcke, I., 2014. Epigenetic mechanisms in epilepsy. Prog. Brain Res. 213,
279–316.
McClelland, S., Flynn, C., Dube, C., Richichi, C., Zha, Q., Ghestem, A., Esclapez, M., Bernard,
C., Baram, T.Z., 2011. Neuron-restrictive silencer factor-mediated hyperpolarization-
activated cyclic nucleotide gated channelopathy in experimental temporal lobe
epilepsy. Ann. Neurol. 70, 454–464.
Pallud, J., Haussler, U., Langlois, M., Hamelin, S., Devaux, B., Deransart, C., Depaulis, A.,
2011. Dentate gyrus and hilus transection blocks seizure propagation and granule
cell dispersion in a mouse model for mesial temporal lobe epilepsy. Hippocampus
21, 334–343.Peng, Z., Huang, C.S., Stell, B.M., Mody, I., Houser, C.R., 2004. Altered expression of the
delta subunit of the GABAA receptor in a mouse model of temporal lobe epilepsy.
J. Neurosci. 24, 8629–8639.
Pitsch, J., Schoch, S., Gueler, N., Flor, P.J., van der Putten, H., Becker, A.J., 2007. Functional
role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy.
Neurobiol. Dis. 26, 623–633.
Rakhade, S.N., Jensen, F.E., 2009. Epileptogenesis in the immature brain: emerging
mechanisms. Nat. Rev. Neurol. 5, 380–391.
Riban, V., Bouilleret, V., Pham-Le, B.T., Fritschy, J.M., Marescaux, C., Depaulis, A., 2002.
Evolution of hippocampal epileptic activity during the development of hippocampal
sclerosis in a mouse model of temporal lobe epilepsy. Neuroscience 112, 101–111.
Schwarzer, C., Tsunashima, K., Wanzenbock, C., Fuchs, K., Sieghart, W., Sperk, G., 1997.
GABA(A) receptor subunits in the rat hippocampus II: altered distribution in kainic
acid-induced temporal lobe epilepsy. Neuroscience 80, 1001–1017.
Sharma, A.K., Reams, R.Y., Jordan, W.H., Miller, M.A., Thacker, H.L., Snyder, P.W., 2007.
Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions.
Toxicol. Pathol. 35, 984–999.
Simonato, M., Tongiorgi, E., Kokaia, M., 2006. Angels and demons: neurotrophic factors
and epilepsy. Trends Pharmacol. Sci. 27, 631–638.
Sng, J.C., Taniura, H., Yoneda, Y., 2005. Inhibition of histone deacetylation by trichostatin A
intensiﬁes the transcriptions of neuronal c-fos and c-jun genes after kainate stimula-
tion. Neurosci. Lett. 386, 150–155.
Sng, J.C., Taniura, H., Yoneda, Y., 2006. Histonemodiﬁcations in kainate-induced status ep-
ilepticus. Eur. J. Neurosci. 23, 1269–1282.
Sperk, G., 1994. Kainic acid seizures in the rat. Prog. Neurobiol. 42, 1–32.
Sperk, G., Lassmann, H., Baran, H., Kish, S.J., Seitelberger, F., Hornykiewicz, O., 1983. Kainic
acid induced seizures: neurochemical and histopathological changes. Neuroscience
10, 1301–1315.
Sperk, G., Marksteiner, J., Gruber, B., Bellmann, R., Mahata, M., Ortler, M., 1992. Functional
changes in neuropeptide Y- and somatostatin-containing neurons induced by limbic
seizures in the rat. Neuroscience 50, 831–846.
Sperk, G., Wieselthaler-Holzl, A., Pirker, S., Tasan, R., Strasser, S.S., Drexel, M., Piﬂ, C.,
Marschalek, J., Ortler, M., Trinka, E., Heitmair-Wietzorrek, K., Cioﬁ, P., Feucht, M.,
Baumgartner, C., Czech, T., 2012. Glutamate decarboxylase 67 is expressed in hippo-
campal mossy ﬁbers of temporal lobe epilepsy patients. Hippocampus 22, 590–603.
Szabo, G., Kartarova, Z., Hoertnagl, B., Somogyi, R., Sperk, G., 2000. Differential regulation
of adult and embryonic glutamate decarboxylases in rat dentate granule cells after
kainate-induced limbic seizures. Neuroscience 100, 287–295.
Timmusk, T., Palm, K., Metsis, M., Reintam, T., Paalme, V., Saarma, M., Persson, H., 1993.
Multiple promoters direct tissue-speciﬁc expression of the rat BDNF gene. Neuron
10, 475–489.
Tsankova, N.M., Kumar, A., Nestler, E.J., 2004. Histone modiﬁcations at gene promoter
regions in rat hippocampus after acute and chronic electroconvulsive seizures.
J. Neurosci. 24, 5603–5610.
Tsunashima, K., Schwarzer, C., Kirchmair, E., Sieghart,W., Sperk, G., 1997. GABA(A) receptor
subunits in the rat hippocampus III: altered messenger RNA expression in kainic
acid-induced epilepsy. Neuroscience 80, 1019–1032.
Vezzani, A., Sperk, G., 2004. Overexpression of NPY and Y2 receptors in epileptic brain
tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?
Neuropeptides 38, 245–252.
Vezzani, A., French, J., Bartfai, T., Baram, T.Z., 2011. The role of inﬂammation in epilepsy.
Nat. Rev. Neurol. 7, 31–40.
Voelter-Mahlknecht, S., Ho, A.D., Mahlknecht, U., 2005. Chromosomal organization and
localization of the novel class IV human histone deacetylase 11 gene. Int. J. Mol.
Med. 16, 589–598.
Wasterlain, C.G., 1972. Breakdown of brain polysomes in status epilepticus. Brain Res. 39,
278–284.
Williams, P.A., White, A.M., Clark, S., Ferraro, D.J., Swiercz, W., Staley, K.J., Dudek, F.E.,
2009. Development of spontaneous recurrent seizures after kainate-induced status
epilepticus. J. Neurosci. 29, 2103–2112.
Yao, Z.G., Zhang, L., Huang, L., Zhu, H., Liu, Y., Ma, C.M., Sheng, S.L., Qin, C., 2013. Regional
and cell-type speciﬁc distribution of HDAC2 in the adult mouse brain. Brain Struct.
Funct. 218, 563–573.
